1147 GMT - Novartis's 2025 guidance lift for both sales and profits should be well-received among investors, Jefferies analysts say in a note. The Swiss drugmaker's higher revenue, a better gross margin and lower R&D spend drove its core operating income above consensus, the analysts say. "We believe we could see a continuing beat-and-raise story this year," they say. Shares rise 0.7% to 94.04 euros.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
Novartis shares rise 0.7% to 94.04 Swiss francs. "Novartis Guidance Lift Seems Positive Signal for Investors -- Market Talk," at 1147 GMT, misstated the currency.
(END) Dow Jones Newswires
April 29, 2025 07:54 ET (11:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.